AD-214 well tolerated in Phase I extension study
Released
Released
Announcement PDF
23 October 2023
ASX Announcement
AD-214 PHASE I EXTENSION: FAVOURABLE TOLERABILITY AFTER THIRD DOSE
Key points
• Eight healthy volunteers have now received three doses of AD-214 in Phase I
extension study
• Study investigators continue to report no safety concerns, confirming
favourable tolerability profile from lower doses
• Headline pharmacokinetic and receptor engagement data still anticipated
November 2023 for ongoing, advancing partnering discussions
MELBOURNE Australia, 23 October 2023: AdAlta Limited (ASX:1AD), the clinical stage
company developing novel protein and cell therapeutic products from its i-body® platform, is
pleased to report that all healthy volunteers in its AD-214 Phase I extension study have now
successfully received three doses, enabling pharmacokinetic and receptor engagement
analysis to be completed on schedule and confirming the favourable tolerability profile
observed at lower doses.
AD-214 is AdAlta’s lead drug candidate, which is being developed as a first-in-class therapy
to treat debilitating and fatal fibrotic (scarring) diseases including Idiopathic Pulmonary
Fibrosis (IPF). The Phase I extension study 1 is designed to assess the safety and availability
of multiple 10 mg/kg intravenous doses of AD-214, which is the highest dose anticipated to
be used in forthcoming Phase II clinical studies.
All eight participants have now successfully received three doses of AD-214 or placebo.
Dr Tim Oldham, CEO and Managing Director, commented:
“We continue to be grateful to the volunteers participating in this Phase I extension study.
The favourable safety profile of AD-214 continues to be demonstrated at the anticipated
Phase II clinical study doses.
“This study also supports our partnering program for AD-214 and we are pleased to have
materially progressed several partnering and project financing discussions over the past
month to help progress AD-214 into Phase II studies.”
Study investigators have reported no dose limiting toxicity, no need to interrupt doses and no
requirement to administer medication to manage infusion reactions. The frequency of mild
infusion related reactions appears lower than that observed at lower doses in the original
Phase I study. 2
Full pharmacokinetic and receptor engagement analysis and then updated dose finding
simulations can now commence and remain on schedule for discussion with partners in
November 2023. The study participants will receive a final dose in twelve weeks with the aim
of confirming that there is no immune response to AD-214 that might affect efficacy and
safety. Full safety and tolerability results are due in the March Quarter of 2024.
Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
October 2023
1
2
ASX releases 29 June 2023 and 4 August 2023
ASX release 19 July 2021
Shareholders: please update your communication preferences
We encourage shareholders to update their share registry preferences
to receive all communications electronically. Doing so helps us
communicate with you in a time-efficient manner on important matters,
while minimising our mail costs and environmental impact.
Simply click here or scan the QR code and follow the instructions.
Not a shareholder, but want to keep across our progress? Click here to
subscribe to our updates using the Stay in Touch form.
Notes to Editors
About AdAlta
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia.
The Company is using its proprietary i-body technology platform to solve challenging drug targeting
problems and generate a promising new class of single domain antibody enabled protein and cell
therapeutics with the potential to treat some of today’s most challenging medical conditions.
The i-body technology mimics the shape and stability of a unique and versatile antigen binding
domain that was discovered initially in sharks and then developed as a human protein. The result is
a range of unique proteins capable of interacting with high selectivity, specificity and affinity with
previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are
implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold
and the first based on the shark motif to reach clinical trials.
AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being
developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases
for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for
Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in
the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of its i-body
platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body
enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an
agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging)
against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in
preclinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by
internally discovering and developing selected i-body enabled product candidates against GPCRs
implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical
companies to develop product candidates against other classes of receptor, in other indications, and
in other product formats.
Further information can be found at: https://adalta.com.au
For more information, please contact:
Investors
Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au
Media
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au
Share your feedback
Discover